RE: delay17 Oct 2022 21:49
not necessarily bothwell.imo all that has changed with the rights issue is the level of dilution.the prospects for approval by fda remain the same,but hopefully we will have a bit more cash to keep us going till then(not a lot i realise but at least something)also mellon is going be committed to a greater extent.iappreciale he could write it all off as a small change loss,but however you look at it it is still millions and i expect he will not want to give up without a fight(i hope!).so barring the dilution, we could view it as being in a better position.im hoping the dilution is not at the top end of the possible scale(just under 60%) but closer to 40%, but that's just a guess.whilst I've revised down my personal expectations as to the figure at which i might feel obliged to exit due to age etc,it's still perfectly possible imo to get there even with dilution by end of 2023 if fda goes well. my immediate concern is to see the rights issue go through,as its not a given,although i would be very surprised if they don't get it through at the end of the day. all just my opinion of course.